Trials / Terminated
TerminatedNCT00126230
Trial of Docetaxel-Samarium in Patients With Hormone-Refractory Advanced Prostate Cancer
A Prospective Phase II Trial of Docetaxel-Samarium in Patients With Hormone-Refractory Advanced Prostate Cancer Who Achieve a Response or a Stabilization to Docetaxel-Estramustine
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 55 (planned)
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris · Academic / Other
- Sex
- Male
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective phase II trial of docetaxel-samarium in patients with hormone-refractory advanced prostate cancer who achieve a response or a stabilization to docetaxel-estramustine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | docetaxel and samarium |
Timeline
- Start date
- 2004-01-01
- First posted
- 2005-08-03
- Last updated
- 2006-09-11
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT00126230. Inclusion in this directory is not an endorsement.